Jodi Devlin, who serves as Chief of Clinical Operations at TriSalus Life Sciences, Inc. (NASDAQ: TLSI), executed three separate insider sales totaling 3,107 shares of common stock between March 11 and March 16, 2026. The aggregate proceeds from those dispositions amounted to $13,171, with execution prices ranging from $4.09 to $4.13 per share.
The individual transactions were recorded as follows: on March 11 Devlin sold 1,162 shares at $4.13 per share; on March 12 she sold 1,772 shares at $4.09 per share; and on March 16 she sold a further 273 shares at $4.12 per share. After completing these sales, Devlin directly holds 97,364 shares of TriSalus common stock.
At the time of these reports, TriSalus stock was trading at $3.92, a level noted as being 45% lower year-to-date. The company is scheduled to release financial results on March 26, which is six days after the latest recorded sale. The pending earnings report will follow a period in which the company disclosed notable revenue increases alongside an ongoing operating loss.
For the fourth quarter of fiscal 2025 TriSalus reported revenue of $13.2 million, a 60% increase compared with the same quarter of the prior year. Management attributed this growth to improved manufacturing efficiencies and an expanded product mix. Despite the revenue gain, the company posted a net operating loss of $3.3 million for the quarter, an improvement from a $7.6 million operating loss in the comparable quarter a year earlier.
On a fiscal year basis TriSalus reported $45 million in revenue for 2025, a 53% increase over fiscal 2024. Following the company’s earnings publication, Jones Trading maintained a Buy rating on TriSalus and set a price target of $11.00 after holding a follow-up call with company management.
TriSalus also disclosed research activity in the scientific journal Frontiers in Oncology. The company published preclinical data evaluating its Pressure-Enabled Drug Delivery, or PEDD, technology for administering nelitolimod in liver tumor models. The study compared PEDD to conventional delivery approaches using both porcine and murine liver tumor models.
In analyst and subscriber materials referenced by the company, an InvestingPro analysis concluded that the stock appears undervalued at current levels. Investors seeking deeper research were pointed to Pro Research Reports covering TLSI and other U.S. equities.
The insider sales by the clinical chief come as TriSalus balances revenue growth and narrowing operating losses while preparing to report near-term results. The company’s recent research publication and the reiterated analyst rating were both highlighted in investor communications that accompanied the quarter’s financial disclosures.